PG
BMRN icon

PEAK6 Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

PEAK6 Group’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$26.5M Buy
281,700
+25,800
+10% +$2.26M 0.11% 162
2018
Q1 		$20.7M Buy
255,900
+97,200
+61% +$8.34M 0.09% 219
2017
Q4 		$14.2M Buy
158,700
+37,700
+31% +$3.28M 0.07% 336
2017
Q3 		$11.3M Buy
121,000
+8,800
+8% +$778K 0.06% 367
2017
Q2 		$10.2M Sell
112,200
-79,300
-41% -$7.21M 0.06% 367
2017
Q1 		$16.8M Buy
191,500
+98,500
+106% +$8.76M 0.14% 159
2016
Q4 		$7.7M Sell
93,000
-400
-0.4% -$34.4K 0.06% 469
2016
Q3 		$8.64M Buy
93,400
+21,100
+29% +$1.99M 0.06% 413
2016
Q2 		$5.63M Sell
72,300
-21,500
-23% -$1.83M 0.04% 607
2016
Q1 		$7.74M Buy
93,800
+31,200
+50% +$2.54M 0.06% 420
2015
Q4 		$6.56M Buy
62,600
+6,100
+11% +$637K 0.04% 571
2015
Q3 		$5.95M Buy
56,500
+13,700
+32% +$1.83M 0.03% 762
2015
Q2 		$5.85M Buy
42,800
+24,200
+130% +$3M 0.03% 736
2015
Q1 		$2.32M Sell
18,600
-17,900
-49% -$1.9M 0.02% 1163
2014
Q4 		$3.3M Buy
+36,500
New +$3.04M 0.02% 921
2014
Q3 		– Sell
-100
Closed -$6K – 4682
2014
Q2 		$6K Hold
100
– – ﹤0.01% 4474
2014
Q1 		$7K Sell
100
-9,900
-99% -$730K ﹤0.01% 4727
2013
Q4 		$704K Sell
10,000
-20,700
-67% -$1.41M ﹤0.01% 2357
2013
Q3 		$2.22M Buy
30,700
+28,200
+1,128% +$1.87M 0.02% 1445
2013
Q2 		$139K Buy
+2,500
New +$156K ﹤0.01% 3897

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

PEAK6 Group's BMRN Position: Q2 2018 in Review

PEAK6 Group reduced its BioMarin Pharmaceuticals (BMRN) stake by 25% in Q2 2018, selling an estimated $2.53M and leaving 87,517 shares worth $8.24M. The position accounts for 0.04% of the portfolio, ranked #533.

PEAK6 Group first reported a position in BMRN in Q2 2013 and has held it in 17 quarters since. The position peaked at $9.43M in Q1 2018. 449 funds tracked by Wall St. Rank hold BMRN as of Q2 2018.

  • PEAK6 Group held 87,517 shares of BioMarin Pharmaceuticals worth $8.24M as of Q2 2018.
  • PEAK6 Group sold 28,857 BioMarin Pharmaceuticals shares in Q2 2018, an estimated $2.53M.
  • BioMarin Pharmaceuticals made up 0.04% of PEAK6 Group's portfolio in Q2 2018, its #533 holding.
  • PEAK6 Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 17 quarters since.
  • PEAK6 Group's BioMarin Pharmaceuticals position peaked at $9.43M in Q1 2018.
  • 449 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.